Advertisement

Gastrointestinal Disorders

 
Daily Dose: Autoimmune Disorders Associated with New-onset Atrial Fibrillation
January 10, 2023

Your daily dose of clinical news you may have missed.

Daily Dose: Universal DAA Therapy for all Persons with HCV
January 09, 2023

Your daily dose of clinical news you may have missed.

Autoimmune Disorders Associated with New-onset AF and More Distinct in Women, Shows New Study
January 09, 2023

Findings elaborate on the pathophysiological differences in autoimmunity and atrial fibrillation risk between men and women.

New Findings Underscore Need for Universal DAA Therapy for all Persons with Hepatitis C Virus Infection
January 06, 2023

Direct-acting antiviral treatment was independently associated with a lower risk of mortality and liver and nonliver outcomes in a large study of adults with chronic hepatitis C.

Ulcerative Colitis May be an Independent Risk Factor for Hypertension: UK Biobank Analysis
January 06, 2023

The analysis of nearly 300 000 individuals found those with IBD were more likely than the general population to have hypertension and that only UC was independently associated.

Daily Dose: Acupuncture for Irritable Bowel Syndrome
January 04, 2023

Your daily dose of clinical news you may have missed.

Acupuncture May be a Viable, Effective Treatment Option for IBS, Suggests New Research
January 03, 2023

In patients with IBS-D, 2 types of acupuncture delivered substantial improvements in abdominal pain score and frequency of loose stool after 4 weeks of treatment.

Butryate Supplementation May Support Pediatric Obesity Treatment
December 07, 2022

Findings from a new study suggest that supplementing standard care for obesity with butyrate helped reduce BMI, improve glucose metabolism, and reduce inflammation markers.

First Live Microbiota Treatment for Recurrent CDI Wins FDA Approval
December 01, 2022

The single-dose biotherapeutic remained effective through 6 months for more than 90% of phased 3 clinical trial participants, according to Ferring Pharmaceuticals.

Dupilumab Pooled Phase 3 Trial Data Broadly Support FDA Approval for EoE
November 15, 2022

Pooled phase 3 data from LIBERTY-EoE-TREET presented at ACAAI 2022 reinforce May 2022 FDA approval of dupilumab for eosinophilic esophagitis.

Advertisement
Advertisement